drugset / Trial / NCT00696137

Long-term Extension Study of BEMA™ Fentanyl

NCT00696137

Phase 3 Completed 5 enrolled BioDelivery Sciences International
NaSingle-groupOpen-labelTreatment

Summary

This study is designed to provide continued access to BEMA Fentanyl for those subjects who previously participated in FEN-202 and who wish to continue using BEMA Fentanyl for the treatment of their breakthrough cancer pain.

Timeline

Start
2008-06
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Fentanyl Other / unclassified 200 ug Other
Subject Fentanyl Other / unclassified 400 ug Other
Subject Fentanyl Other / unclassified 600 ug Other
Subject Fentanyl Other / unclassified 800 ug Other
Subject Fentanyl Other / unclassified 1200 ug Other